Ovid Therapeutics (OVID) Short term Debt (2019 - 2020)
Ovid Therapeutics (OVID) posted Short term Debt of $2.4 million for Q4 2020, up 946.63% on a QoQ basis from $226536.0 in Q3 2020, and up 21845.5% year-over-year from N/an in Q1 2020.
Ovid Therapeutics (OVID) Short term Debt (2019 - 2020) Analysis & Trends
Ovid Therapeutics' Short term Debt history runs 2 years deep, the most recent figure standing at $2.4 million for Q4 2020.
- Quarterly Short term Debt rose 21845.5% year-over-year to $2.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $2.4 million (up 21845.5% YoY) and the FY2020 annual result came in at $2.4 million, up 21845.5% from the prior year.
- Short term Debt was $2.4 million for Q4 2020 at Ovid Therapeutics, up from $226536.0 in the prior quarter.
- Across five years, Short term Debt topped out at $2.4 million in Q4 2020 and bottomed at $10804.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Ovid Therapeutics | 118.66 Mn | -36.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 2.37 Mn |
| Sep 30, 2020 | 226,536.00 |
| Jun 30, 2020 | 10,804.00 |
| Mar 31, 2020 | 10,804.00 |
| Dec 31, 2019 | 10,804.00 |
| Sep 30, 2019 | 337,773.00 |
| Jun 30, 2019 | 1.06 Mn |